Prof. Andrew M. Scott MB BS (Hons), MD, FRACP, DDU, FAICD, FAANMS Graduated in Medicine from the University of Sydney (MB BS - Hons), and trained in Internal Medicine, Nuclear Medicine and Tumour Immunology in Sydney, and at Memorial Sloan-Kettering Cancer Center, USA. His current appointments include Member and Laboratory Head, Ludwig Institute for Cancer Research, Melbourne-Austin Branch; Professor, Department of Medicine, University of Melbourne; and Director, Centre for Positron Emission Tomography (PET), Austin Hospital. Prof. Scott is President-elect of the World Federation of Nuclear Medicine and Biology. He is also a Board member of the Australian Nuclear Science and Technology Organisation, Clinical Trials Australia, and the Victorian Cancer Biobank. His research is focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies and cell signalling inhibition, and in oncology applications in PET, both in staging and molecular characterisation of tumours. He has been involved in the preclinical development and first-in-man trials of eight recombinant antibodies in cancer patients, and five antibodies from his program have recently been licenced to Biotech and Pharma companies. Prof. Scott has over 235 peer reviewed publications, 10 invited reviews and 19 book chapters principally in cancer research and PET. He has been the Principal Investigator of research grants from NHMRC, US National Institutes of Health, Australian Cancer Research Foundation, Cancer Council Victoria, Harry J Lloyd Foundation, Komen Foundation, and the Australian Government.